Stock comparison
Haemonetics
Takeda Pharmaceutical Company Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
TAK
Takeda Pharmaceutical Company Limited
Market cap
$51.34B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | TAK | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 44D | HAE |
| Benjamin Graham | 85A | 56C | HAE |
| Philip Fisher | 60C | 40D | HAE |
| Peter Lynch | 54C | 18F | HAE |
| Joel Greenblatt | 31F | 32F | TAK |
| Charlie Munger | 54D | 41D | HAE |
| Terry Smith | 55D | 36D | HAE |
Side-by-side metrics
| Metric | HAE | TAK |
|---|---|---|
| Market cap | $2.98B | $51.34B |
| P/E (TTM) | 24.8x | 43.0x |
| EV/EBIT | 14.1x | 22.0x |
| ROIC (TTM) | 8.37% | 2.59% |
| Gross margin | 55.74% | 58.76% |
| Net margin | 7.29% | 4.26% |
| Revenue CAGR 5y | 7.65% | 7.56% |
| EPS CAGR 5y | 24.62% | -3.46% |
| Debt / Equity | 1.5x | 0.6x |
| Dividend yield | 0.0% | 3.79% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -3.46%+114%
- ROIC (TTM)8.37%vs 2.59%+69%
- P/E (TTM)24.8xvs 43.0x+42%
- Net margin7.29%vs 4.26%+42%
TAK leads on
- Dividend yield3.79%vs 0.0%+100%
- Market cap$51.34Bvs $2.98B+94%
- Debt / Equity0.6xvs 1.5x+59%
- Gross margin58.76%vs 55.74%+5%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.